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Abstract sue-specific and dose-related changes in tissue T3 concentra-
We have studied whether, or not, tissue-specific regulatory
mechanisms provide normal 3,5,3'-triiodothyronine (T3)
concentrations simultaneously in all tissues of a hypothyroid
animal receiving thyroxine (T4), an assumption implicit in
the replacement therapy of hypothyroid patients with T4
alone.
Thyroidectomized rats were infused with placebo or 1
of 10 T4 doses (0.2-8.0 ,ug per 100 grams of body weight
per day). Placebo-infused intact rats served as controls.
Plasma and 10 tissues were obtained after 12-13 d of infu-
sion. Plasma thyrotropin and plasma and tissue T4 and T3
were determined by RUI. Iodothyronine-deiodinase activi-
ties were assayed using cerebral cortex, liver, and lung.
No single dose of T4 was able to restore normal plasma
thyrotropin, T4 and T3, as well as T4 and T3 in all tissues,
or at least to restore T3 simultaneously in plasma and all
tissues. Moreover, in most tissues, the dose of T4 needed to
ensure normal T3 levels resulted in supraphysiological T4
concentrations. Notable exceptions were the cortex, brown
adipose tissue, and cerebellum, which maintained T3 ho-
meostasis over a wide range of plasma T4 and T3 levels.
Deiodinase activities explained some, but not all, of the tis-
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1. Abbreviations used in this paper: 5 'D-I, type I 5'-iodothyronine
deiodinase; 5 'D-II, type II 5 '-iodothyronine deiodinase; SD-III, 5-deio-
dinase; BAT, brown adipose tissue (interscapular pads); BW, body
weight; Cb, cerebellum; Cx, cerebral cortex; d.f., degrees of freedom;
H, heart; K, kidney; L, liver; Lu, lung; Mu, skeletal muscle (musculus
quadriceps femoris); P1, plasma; PTU, 2-N-propyl-6-thiouracil; R2, co-
efficient of determination; rT3, reverse 3,5 ',3 '-triiodothyronine; S,
spleen; T3, 3,5,3 '-triiodothyronine; T3S, 3,5,3 '-triiodothyronine sulfate;
T4, thyroxine; TSH, thyroid-stimulating hormone.
tions.
In conclusion, euthyroidism is not restored in plasma
and all tissues of thyroidectomized rats on T4 alone. These
results may well be pertinent to patients on T4 replacement
therapy. (J. Clin. Invest. 1995. 96:2828-2838.) Key words:
thyroid hormones * triiodothyronine * thyrotropin * iodo-
thyronine-deiodinases * hypothyroid
Introduction
The thyroid gland secretes thyroxine (T4)' and 3,5,3'-triiodo-
thyronine (T3), with T4 as the quantitative major secretory
product in most species studied so far. The molar ratio of the two
iodothyronines, as secreted by the gland, has been calculated as
14:1 in adult humans (1), with the corresponding mean value
obtained for the adult male rat being 6:1 (2-5). Although
thyroidal synthesis and secretion are the only major source of
T4 for extrathyroidal tissues, T3 secreted by the gland represents
a relatively minor source of T3. Intracellular T3 is derived from
two sources: circulating T3, and local conversion of T4 to T3.
The former is, moreover, not entirely derived from the thyroidal
secretion of T3, as a large proportion of circulating T3 has been
generated from T4 in different tissues, and then released into the
circulation. It was initially believed that circulating T3 would be
in rapid and complete exchange with all of the T3 in extrathy-
roidal tissues, whether derived from the circulation or generated
locally from T4. Therefore, under steady state conditions normal
circulating T3 levels ought to ensure normal levels of T3 in all
tissues. Studies from our laboratory (6, 7), however, questioned
this assumption. Triiodothyronine generated locally from T4 is
not necessarily in rapid or complete equilibrium with circulating
T3 in all tissues, and therefore cannot be readily quantified from
serum T3 levels and the tissue to plasma T3 ratio for that tissue,
as determined with labeled T3. This was shown independently
for anterior pituitary nuclear T3 by Silva and Larsen (8), and
the important role of tissue deiodinative pathways for the regula-
tion of intracellular sources of T3 was established (9). Different
iodothyronine deiodinases were characterized and their different
responses to thyroid status established ( 10, 11 ).
The relative contribution of T3 derived as such from the
circulation and T3 generated locally from T4 has been measured
for many tissues in the rat: it is not the same for all tissues
and may, moreover, change in opposite manner in the same or
different tissues during the life cycle, or when the animal is
faced with alterations in thyroid hormone status, metabolic im-
balances, treatments with drugs, etc. (2-5, 12-24). The ob-
served changes in the relative contribution of both tissue sources
of T3 are often in conceptual agreement with changes in the
activities of the different iodothyronine deiodinases, as detected
in vitro, although this is not always the case. Our knowledge
regarding the roles of nondeiodinative pathways of T4 and T3
metabolism in different tissues, or of factors regulating the up-
take and exit of iodothyronines is very fragmentary (25, 26).
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Despite the many gaps in our knowledge, it would appear
likely that those tissues which derive most of their T3 from
the circulation would have normal concentrations of T3 when
circulating T3 levels are normal, whereas those tissues deriving
all or most of their T3 by local generation from T4 would
have normal T3 concentrations when plasma T4 is normal or
somewhat elevated, provided the physiological responses to
changes in thyroid status of the different deiodinases and of
other regulatory mechanisms are not impaired. Normalization
of circulating thyroid-stimulating hormone (TSH) is usually
taken as confirmation that this has occurred. An athyrotic rat
receiving T4 alone in amounts sufficient to ensure normal circu-
lating levels of both iodothyronines ought to be able to compen-
sate for the absence of thyroidal secretion of T3, a relatively
minor source of T3 available to tissues. This assumption, how-
ever, has never been confirmed directly, although it is implicit
in substitution therapies using T4 alone.
The oral administration of L-thyroxine (27, 28) is at present
the widely accepted and recommended form of replacement
therapy of hypothyroidism in humans. It therefore appeared of
interest to clarify directly whether, or not, using T4 alone a
euthyroid status is ensured simultaneously for all tissues. The
experimental approach we have used is the direct determination
of the concentrations of T4 and T3 in several tissues obtained
from thyroidectomized rats on a constant subcutaneous infusion
of T4. As will be seen, none of the 10 doses of T4 which we
tested was adequate to ensure simultaneously a normal thyroid
status of all the tissues studied.
Methods
Experimental design. Young female Wistar rats, weighing 120-150
grams, were surgically thyroidectomized. After 7 d a single 100-yCi
dose of 1311 was injected intraperitoneally to eliminate thyroid remnants.
4 wk later, rats with body weight (BW) stasis were subdivided in groups
of six rats each, and osmotic minipumps (ALZET®, model 2ML2; Alza
Corp., Palo Alto, CA) were implanted under the dorsal skin of the
animals.
Two separate experiments were performed. In experiment A the rats
were infused either with placebo solution or with T4 at doses of 1.0,
2.0, 3.0, 4.0, and 8.0 yg per 100 gram BW per day. In experiment B,
performed half a year later, the thyroidectomized rats were infused either
with placebo or with T4 at doses of 0.2, 0.4, 0.6, 0.8, and 1.6 pg per
100 gram BW per day. In both experiments, a control group of six
intact rats was infused with placebo solution.
After 13 (experiment A) or 12 (experiment B) d of infusion the
rats were slightly anesthetized with ether, bled extensively from the
abdominal aorta after injection of a small amount (30-50 .I) of heparin
(0.17% in 0.9% NaCl), and perfused with 50 ml of PBS (0.05 M
phosphate buffer containing 0.9% NaCl, pH = 7.4). Samples of plasma
(P1), brown adipose tissue interscapular pads (BAT), pituitary, cerebral
cortex (Cx), cerebellum (Cb), liver (L), kidney (K), heart (H), lung
(Lu), spleen (S), and muscle (musculus quadriceps femoris, [Mu]),
were obtained. Samples were rapidly frozen on dry ice and stored at
-20°C until analyzed for the present, or other, studies.
Determinations. Thyroxine and T3 were measured in whole plasma
by specific and highly sensitive RIA as previously described (29), and
in tissues after extraction and purification of the iodothyronines, as
detailed elsewhere (30, 31 ). In brief, methanol is added to the still frozen
tissue sample and homogenized. This avoids postmortem generation of
T3 from T4, and degradation of T4 or T3 (31). Tracer amounts of
[1311]T4 and ['25I]T3 are added to each homogenate. This is followed
by extraction of > 90% of the endogenous and added iodothyronines
using chloroform/methanol (2:1). The iodothyronines are then back-
extracted into an aqueous phase, and purified by passing this aqueous
phase through resin columns (AG 1 x 2; Bio-Rad Laboratories, Rich-
mond, CA). After a pH gradient, the iodothyronines are eluted with
70% acetic acid, which is then evaporated to dryness. Radioimmunoas-
say buffer is added and each extract is extensively counted to determine
the recovery of the ['3'I]T4 and [125I]T3 added to each sample during
the initial homogenization process; recovery usually varies between 50-
60% for ['311]T4 and 60-70% for ['251]T3. The samples are submitted
to highly sensitive RIAs for the determination of T4 and T3, the limits
of sensitivity being 2.5 pg T4 and 1.5 pg T3/tube. Cross-reactivities of
different iodothyronines and metabolites in the T4 and T3 RIAs were
as recently reported (31). Each sample is processed in duplicate or
triplicate at two or more dilutions. Concentrations are then calculated
using the amounts of T4 and T3 found in the respective RIAs, the
individual recovery of the ['311]T4 and [125I]T3 added to each sample
during the initial homogenization process, and the weight of the tissue
sample submitted to extraction. The amounts of tracers added are such
that the radioactivities carried over into the RIA tubes are too low to
interfere with the determinations, representing < 2.5% of the radioactiv-
ity added as labeled antigen.
Both T4 and T3 concentrations of a given tissue were determined
in the same extraction run and a single RIA for each hormone. This
limited the number of animals in one experiment to < 45.
TSH was measured in plasma using immunoreactants kindly pro-
vided by the Rat Pituitary Agency of the National Institute of Diabetes,
Digestive and Kidney Diseases (NIDKK, NIH, Bethesda, MD) as de-
scribed elsewhere (32). Results are expressed in weight equivalents of
the NIDDK r-TSH RP-3 preparation.
Type I 5'-iodothyronine deiodinase (5'D-I activity was assayed in
L and Lu homogenates as described (33), using 400 nM reverse T3
(rT3) and 2 mM DTT for L, and 2 nM rT3, and 20 mM DTT for Lu
in 100 mM potassium phosphate buffer (pH = 7.0), 1 mM EDTA. The
reaction time was 10 min. for L, and 60 min for Lu. Type II 5 'D (5 'D-
II) activity was assayed in the Cx (34) using 2 nM T4+ 1 M1M T3 and
20 mM DTT in the presence of 1 mM 2-N-propyl-6-thiouracil (PTU),
and the reaction time was 60 min. Before each assay [1251] rT3 or
[1 251]T4 was purified by paper electrophoresis to separate the contami-
nating iodide. The 125I-released was separated by ion-exchange chroma-
tography on Dowex-50W-X2 (Bio-Rad Laboratories) columns equili-
brated in 10% acetic acid. The production of equal amounts of iodide
and 3 ',3-diiodothyronine was checked in some assays. The protein con-
tent was determined by the method of Lowry et al. (35), after precipita-
tion of the homogenates with 10% TCA to avoid interferences from
DTT in the colorimetric reaction. Protein was usually 200 gg/100 Ml
for most tissues, except for 10 times less when L was used.
5-deiodinase activity was measured in Cx homogenates (36), incu-
bating 20-50 Mg protein/ 100 Mtl in 100 mM potassium phosphate buffer
(pH = 7.4), 1 mM EDTA with - 50,000 cpm of innerring-labeled
[1251]T3 (3,5-[1251]T3), 50 nM T3, 20 mM DTT, and 1 mM PTU for
60 min. at 37°C. Radioiodide release was measured as above. When
necessary, 3,5- ['251]T3 was purified just before the assay using dispos-
able Sep-Pak C18 cartridges (Waters Associates, Mildford, MA).
Drugs and reagents. Thyroxine, T3, 3,5-diiodothyronine, PTU, and
DTT were obtained from Sigma Chemical Co. (St. Louis, MO). Reverse
T3 and 3 ',3-diiodothyronine were obtained from Henning Berlin Gmbh
(Berlin, Germany).
High specific activity [1311]T4, [1251]T3, ['251]T4, and [1251]rT3
(3,000 yCi/lsg) were synthesized in our laboratory, as previously de-
scribed (30), and used for highly sensitive T4 and T3 RIAs, as recovery
tracers for plasma and tissues extractions, and as substrates for 5'-
deiodinases. The innerring-labeled 3,5-[ 1251]T3 (80 MiCi/Ug), used as
substrate for 5-deiodinase (SD-Ill), was kindly provided by Drs. R.
Thoma and H. Rokos from Henning Berlin Gmbh.
Statistical analysis. One-way ANOVA and protected least signifi-
cant difference test for multiple comparisons were used, after validation
of the homogeneity of variances by the Bartlett-Box F test (37). Square
root or logarithmic transformations usually ensured homogeneity of
variances when this was not found with the raw data. Results are ex-
pressed as means+SEM. P < 0.05 was considered significant in all
comparisons. To assess the relationships between tissue and plasma T3
and T4 concentrations, individual paired data were adjusted to several
Thyroid Hormone Tissue Levels in Thyroidectomized Rats on Thyroxine 2829
Table L Circulating Concentrations of T4, T3, and TSH, and Tissue T4 and T3 Concentrations in Animals from Experiment A
Group C Tx Tx Tx Tx Tx Tx
T4 dose 0 0 1.0 2.0 3.0 4.0 8.0
Pl-T4 37±3 < 5 49±3 69±4 75±2 95±6 95±13
Pl-T3 0.91±0.05 < 0.15 0.93±0.02 1.18±0.02 1.44±0.14 1.81±0.09 1.98±0.15
Pl-TSH 1.55±0.23 47.52±10.77 15.91±3.33 0.7±0.11 0.4±0.01 0.41±0.03 0.42±0.02
Cx-T4 1.51±0.17 0.12±0.01 2.83±0.32 4.85±0.27 4.56±0.48 5.88±0.15 6.36±0.86
Cx-T3 1.92±0.11 0.10±0.02 1.77±0.09 1.73±0.02 1.80±0.21 2.15±0.05 2.23±0.08
Cb-T4 7.43±0.70 0.16±0.01 5.99±1.08 9.02±1.17 15.81±2.57 15.32±1.18 11.48±0.75
Cb-T3 1.63±0.04 0.13±0.02 1.44±0.06 1.88±0.39 1.88±0.20 2.30±0.14 3.25±0.18
BAT-T4 5.31±0.43 2.78±0.34 15.47±3.84 8.18±2.50 3.44±0.43 4.86±1.28 8.58±2.62
BAT-T3 1.79±0.22 0.38±0.04 2.19±0.33 1.96±0.43 1.12±0.09 1.07±0.18 1.98±0.80
L-T4 18.35±0.81 0.24±0.02 20.68±1.83 60.12±7.58 42.77±12.70 64.01±10.99 79.04±3.83
L-T3 2.81±0.23 0.07±0.01 1.32±0.10 2.87±0.23 3.62±0.71 7.71±0.38 7.71±0.30
K-T4 24.79±1.26 0.18±0.00 24.17±2.34 41.99±5.01 58.21±5.38 51.26±4.61 59.70±2.62
K-T3 4.78±0.50 0.09±0.01 3.35±0.04 6.88±0.95 9.86±1.14 9.70±0.73 14.57±0.98
Lu-T4 6.68±0.20 0.21±0.03 8.00±0.39 12.75±0.95 11.48±1.44 9.59±0.91 18.05±0.61
Lu-T3 1.84±0.11 0.10±0.01 1.21±0.03 1.94±0.17 2.87±0.21 2.55±0.32 4.39±0.74
H-T4 5.02±0.40 0.19±0.00 6.37±0.27 9.18±0.59 9.40±0.92 10.80±0.82 14.40±1.44
H-T3 1.47±0.04 0.05±0.00 1.01±0.06 1.67±0.30 2.17±0.20 2.18±0.04 3.68±0.60
Mu-T4 0.89±0.07 0.17±0.00 1.27±0.06 3.04±0.32 1.49±0.15 3.07±0.18 3.98±0.15
Mu-T3 0.44±0.01 0.05±0.00 0.41 ±0.04 0.73±0.04 0.45±0.04 1.04±0.09 1.40±0.18
S-T4 2.79±0.23 0.32±0.04 3.42±0.20 6.55±0.29 6.96±0.91 8.81 ±0.76 10.95±0.66
S-T3 0.76±0.02 0.15±0.02 0.58±0.02 0.95±0.08 1.03±0.12 1.52±0.11 1.72±0.06
Experiment A: Mean (±SEM) values of plasma T4 (ng/ml), T3 (ng/ml), and TSH (ng/ml), and tissue T4 and T3 (ng/gram) concentrations in control
intact rats (C), in thyroidectomized rats (Tx) infused with placebo, and Tx rats infused with T4. The doses are in Ag T4/100 grams BW per day.
curves (linear, power, inverse, sigmoidal, and logarithmic). The curve
fit with the highest coefficient of determination (R2), degrees of freedom
(d.f.), and F statistics, was selected for each tissue. Statistical analyses
were performed with the SPSS Base System Software for the Macintosh
version 4.0 and SPSS for Windows version 6.0 (SPSS Inc., Chi-
cago, IL).
only reached normal levels with the doses of 1.0 and 1.6 ,ig
T4/ 100 grams BW per day, remaining low in the rats infused
with lower doses of T4 or placebo, and elevated with higher
doses of T4. Plasma TSH was elevated in the rats infused with
placebo or T4 at doses from 0.2 to 1.0 ,g T4/100 grams BW
per day, normal in the rats infused with 1.6 tzg T4/100 grams
Results
Circulating T4, T3, and TSH, and concentrations of T4
and T3 in different tissues as function of the T4 dose
Tables I and II show the circulating T4, T3, and TSH levels,
and the tissue T4 and T3 concentrations for the different groups
of rats from experiments A and B, respectively, with the sig-
nificance of differences versus the respective control group
schematically summarized in Table III.
To be able to combine the results from both experiments,
and to compare the degree of the changes observed in the plasma
with those found in different tissues, the T4, T3, and TSH
concentrations in samples from each thyroidectomized rat, and
from each thyroidectomized rat on the different T4 doses, are
expressed in figures and further tables as percentages of the
mean value corresponding to the group of intact controls, taken
as 100%.
Plasma T4, T3, and TSH. Fig. 1 shows changes in their
concentrations as a function of the T4 dose infused into the
thyroidectomized rats. Plasma T4 was low in the groups of
thyroidectomized rats infused with placebo or with T4 at doses
of 0.2 and 0.4 ,tg/ 100 grams BW per day, normal in the groups
infused with 0.6, 0.8, and 1.0 jtg T4/100 grams BW per day,
and elevated in the groups infused with 1.6, 2.0, 3.0, 4.0, and
8.0 ,4g T4/ 100 grams BW per day. On the contrary, plasma T3
0
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Figure 1. (A) The
changes in plasma T4
and T3 concentration
(full and empty circles,
respectively) of thyroid-
ectomized rats, infused
with placebo or T4, as a
function of the dose of
T4. Values shown are
means (±SEM), and are
expressed as percentages
of the mean value found
for control intact ani-
mals. The areas enclosed
by horizontal lines repre-
sent the 95% confidence
intervals of the plasma
T4 (full lines, dotted
area) or T3 (dotted
lines, white area) of in-
tact control rats. (B) The
corresponding changes
in circulating TSH, su-
perimposed on those of
normal controls (hori-
zontal dotted area).
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Table II. Circulating Concentrations of T4, T3, and TSH, and Tissue T4 and T3 Concentrations in Animals from Experiment B
Group C Tx Tx Tx Tx Tx Tx
T4 dose 0 0 0.2 0.4 0.6 0.8 1.6
PI-T4 35±4 < 5 < 5 17±1 33±4 38±2 67±5
Pl-T3 0.79±0.09 < 0.15 0.22±0.03 0.36±0.03 0.52±0.05 0.64±0.02 0.84±0.03
PI-TSH 0.55±0.01 51.59±6.65 31.14±4.67 69.48±4.32 18.4±3.52 18.56±2.16 0.77±0.17
Cx-T4 4.00±0.39 0.71±0.01 0.84±0.06 1.24±0.12 1.99±0.13 2.65±0.37 6.26±0.88
Cx-T3 1.93±0.04 0.19±0.04 1.27±0.05 2.13±0.15 2.11±0.05 2.07±0.10 2.34±0.10
Cb-T4 5.05±0.81 0.51±0.02 1.23±0.15 3.29±0.36 5.93±0.26 7.60±0.27 12.89±1.00
Cb-T3 2.14±0.14 0.13±0.00 0.85±0.08 1.59±0.08 1.74±0.04 1.94±0.06 2.14±0.08
BAT-T4 6.32±0.66 0.46±0.05 1.56±0.21 6.38±0.48 5.47±0.73 11.67±0.90 24.79±3.25
BAT-T3 3.10±0.28 0.13±0.01 1.02±0.06 1.95±0.22 2.56±0.20 3.79±0.08 2.04±0.17
L-T4 33.20±2.36 0.91±0.20 4.01±0.62 14.98±0.3 1 20.91±0.51 26.00±0.77 61.33±2.51
L-T3 4.69±0.28 1.60±0.43 0.91±0.09 1.93±0.08 2.21±0.05 3.00±0.13 4.66±0.16
K-T4 18.63±1.72 0.42±0.09 2.67±0.24 6.99±1.08 11.97±1.07 13.62±0.61 31.05±1.29
K-T3 5.48±0.37 1.43±0.19 1.90±0.27 2.43±0.16 3.12±0.20 4.33±0.34 5.98±0.09
Lu-T4 7.59±0.86 0.26±0.02 1.42±0.25 3.83±0.71 6.15±0.28 8.80±0.82 14.31±1.23
Lu-T3 2.95±0.21 0.08±0.01 0.71±0.07 1.28±0.16 1.39±0.07 1.82±0.18 2.24±0.19
H-T4 4.42±0.84 0.32±0.05 0.91±0.10 1.51±0.17 3.20±0.16 5.36±1.37 5.59±0.50
H-T3 1.66±0.04 0.12±0.01 0.37±0.03 0.60±0.07 1.24±0.06 1.20±0.07 1.14±0.13
Mu-T4 1.16±0.18 0.19±0.02 0.41±0.03 1.12±0.05 1.55±0.21 1.76±0.11 3.97±0.13
Mu-T3 0.63±0.06 0.06±0.00 0.24±0.02 0.38±0.01 0.41±0.04 0.55±0.04 0.77±0.02
S-T4 3.61±0.43 0.68±0.09 0.73±0.12 2.14±0.26 4.42±0.34 4.87±0.22 8.56±0.69
S-T3 0.89±0.05 0.16±0.03 0.32±0.03 0.48±0.04 0.73±0.04 0.84±0.02 1.38±0.06
Experiment B: Mean (±SEM) values of plasma T4 (nglml), T3 (nglml) and TSH (nglml), and tissue T4 and T3 (ng/gram) concentrations in control
intact rats (C), in thyroidectomized rats (Tx) infused with placebo, and Tx rats infused with T4. The doses are in tig T4/100 grams BW per day.
BW per day, and low in the animals infused with higher doses.
In summary, none of the 10 T4 doses which we infused, and
which ranged from 0.2 to 8.0 jLsg T4/ 100 grams BW per day,
was able to normalize simultaneously plasma T4, T3, and TSH:
T4 and T3 were normal with the infusion of 1.0 jsg T4/ 100
grams BW per day, but TSH remained elevated; with the infu-
sion of 1.6 /ig T4/100 grams BW per day T3 and TSH were
normal, but T4 was elevated. Thus, supraphysiological levels
of plasma T4 were needed to normalize plasma TSH.
Tissue T4 and T3. Fig. 2 shows their changes in several
tissues as a function of the T4 dose. As may be seen, the degree
of increase of T4 and T3 was not the same for all tissues
studied. Thus, with the highest dose of T4 that was infused, the
concentration of T4 increased fourfold, or more, in Cx, L, S,
Table 111. Schematic Representation of Plasma Concentrations of T4, T3, and TSH, and Tissue Levels of T4 and T3, in Thyroidectomized
Rats Infused with Different Doses of T4 with Respect to Age- and Sex-matched Controls*
Dose of T41 0.2 0.4 0.6 0.8 1.0 1.6 2.0 3.0 4.0 8.0
(jig/100 grams
Bw per day) T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH
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* The symbols represent the comparison of the mean values of the T4-infused rats with control rats infused with placebo: = indicates that there
were no statistically significant differences; -w' identifies low levels as compared to controls, with at least P < 0.05; a. identifies elevated levels
as compared to controls, with at least P < 0.05. An open arrow ( or <Q.) indicates that, although statistically significant, the change with respect
to controls was relatively small, within the ±30% of the mean of the control group. *The bold numbers indicate the doses of T4 used in experi-
ment A.
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and Mu, but only two- to threefold in BAT, Cb, Lu, H, and K.
The same occurred with the degree of increase in T3, which
was different for different tissues.
Moreover, the dose needed to ensure a normal concentration
of each iodothyronine (see Table III) was not the same for all
tissues studied. In general, normal tissue T4 levels were
achieved with lower T4 doses than the ones needed to normalize
tissue T3. Conversely, supraphysiological T4 levels were
needed to normalize T3 levels in most tissues. In several tissues
T3 only became normal when normal or supraphysiological
plasma T3 concentrations were reached.
In most tissues, normal concentrations of T4 are not reached
until the dose of T4 is sufficient to result in normal circulating
T4. Thus, the lowest of such doses, namely 0.6 Mg T4/ 100
grams BW per day, resulted in normal T4 concentrations in the
heart, lung, spleen, and cerebellum, although higher doses were
needed to normalize liver and kidney T4. An interesting excep-
tion is the skeletal muscle, where T4 was already normal in the
thyroidectomized rats infused with only 0.4 Mig T4/100 grams
BW per day, a dose which is insufficient to normalize circulat-
ing T4.
The minimal dose of T4 which resulted both in normal
circulating T4 and T3, namely 1.0 Mg T4/100 grams BW per
0T3
i)~A~4 Figure 2. The changes in concentra-
17 tions of T4 (full circles) and T3
_1/ air -- ~~ (empty circles) in different tissues of
I ithyroidectomized rats, infused with
placebo or T4 are shown as function
of the T4 dose. Expression of data and
J1 IIIIIIIIIII meaning of dotted and white areas is
1_ 1111111i23i5678!Ithe same as indicated in the legend toI0 1 3 4 5 6 978 ~ Fig. 1 A. The concentrations of T4 in
BAT of T4-infused animals are not
shown, for reasons outlined in the
text.
day, was insufficient to normalize the concentration of T3 in
most tissues, which required T4 doses resulting in supraphysio-
logical circulating T4. Notable exceptions are, however, the Cx,
BAT, and Cb, tissues which showed a remarkable degree of
independence from plasma T4 and T3 levels: normal or near
normal T3 concentrations were found over a wide range of T4
doses. Cerebral cortex T3 concentrations were low in thyroidec-
tomized rats infused with placebo or 0.2 ,ug T4/ 100 grams BW
per day, but presented normal T3 levels with doses ranging from
0.4 to 8.0 ,tg T4/ 100 grams BW per day (with the exception of
mildly elevated levels in the group of thyroidectomized rats
infused with 1.6 Mug T4/ 100 grams BW per day). This excellent
T3 homeostasis was independent of plasma T4 and T3 levels,
and of T4 levels in the Cx, which were low with 0.2 to 0.8 Iug
T4/ 100 grams BW per day, and elevated with doses of 1.0 to 8.0
Mg T4/ 100 grams BW per day. Similar results were observed in
BAT and, to a lesser degree, in Cb.
Triiodothyronine concentrations in BAT were low in rats
infused with placebo or with 0.2 and 0.4 Mg/100 grams BW
and normal with most of the doses ranging from 0.6 to 8.0 Mg
T4/100 grams BW per day. Thyroxine concentrations in BAT
were low in thyroidectomized rats infused with placebo, and
highly variable in the T4-infused groups, both between and
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Figure 3. Changes in cir-
culating T3 levels of thy-
roidectomized rats, in-
fused with placebo or T4,
as a function of circulat-
ing T4. Expression of
data and meaning of dot-
ted and white areas is the
same as indicated for Fig.
1 A. The diagonal line
corresponds to the rela-
tionship which would be
found if changes in circu-
lating T4 were accompa-
nied by changes of equal
intensity in plasma T3.
among the different groups. These T4 values might be ques-
tioned because of the proximity of the interscapular BAT pads
to the site where the osmotic pump is implanted, and from
which it is only separated by an easily punctured thin layer of
connective tissue. Although care was taken at autopsy to avoid
contact between the BAT pads and fluid surrounding the T4-
containing pumps, some external contamination with T4 might
have occurred. For this reason T4 values in BAT are not shown
in further figures and tables.
Cerebellar T3 was low in rats infused with placebo, 0.2,
0.4, and 0.6 Mg T4/ 100 grams BW per day, normal with 0.8 to
3.0 Mug T4/100 grams BW per day, and elevated with 4.0 and
8.0 Mtg T4/100 grams BW per day. Cerebellar T4 levels were
low in rats infused with placebo, 0.2, and 0.4 pgf100 grams
BW and day, normal with 0.6, 1.0, and 2.0 Mg/100 grams BW
and day, and elevated with 0.8, 1.6, 3.0, and 8.0 4g T4/100
grams BW per day.
Concentrations of T4 and T3 in different tissues as
function of circulating T4 and T3
It appeared interesting to define the relationship between circu-
lating and tissue concentrations of T4 and T3, irrespective of
the dose of T4. Fig. 3 shows changes in plasma T3 as a function
of plasma T4. Plasma T4 levels varied, for thyroidectomized
rats on placebo and those infused with the highest T4 dose,
between 14 (limit of detection) and 352% of the mean T4 value
for control rats, and circulating T3 varied between 16 and 245%
of the mean T3 value of the controls. The relationship is not
the linear one expected if the changes in circulating T3 were
of the same magnitude as those of T4. The closest fit to the
individual paired plasma data was found for the power function:
T3 = 2.62 * T4075, (with d.f. = 49, R2 = 0.96, and P < 0.001).
As indicated before, plasma T3 increases less than T4 in the
hypothyroid range, and supraphysiological plasma T4 levels
have to be reached for normalization of plasma T3.
The concentration of T4 or T3 in each tissue was paired
against the corresponding circulating iodothyronine levels. The
best curve fit within the present range of plasma T4 and T3
concentrations was determined using the individual paired data
from both experiments. Fig. 4 shows some examples of the type
of interrelationships which were found, namely the changes in
T4 and T3 of Cx, Cb, K, and S, as functions of the circulating
T4 and T3 levels, and not, as in Fig. 2, as functions of the
infused dose of T4. These curves and those corresponding to
other tissues are derived from the equations summarized in
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Figure 4. Different examples are shown of the best-fit curves obtained
for the concentrations of T3 or T4 in tissues, as a function of circulating
T4 or T3 levels. Data correspond to the formulas summarized in Tables
AI-AIR. The dotted square inset separates the values below and above
those of control intact rats. The thin diagonal line corresponds to the
relationship which would be found if changes in circulating T4 or T3
were accompanied by changes of equal intensity in the tissues.
Tables AI-AIH of the Appendix. The type of curve fitted to
the individual data, the corresponding equation, as well as the
d.f., R2, and F statistics are shown in these tables. Most of the
curves fitting the tissue T4 or T3 concentrations to the circulat-
ing T4 and T3 levels are not linear, although the exponent in
the power functions ranged from 0.68 to 1.66, and the curves
are almost linear (an exponent = 1.0 corresponds to a linear
function).
It is evident that neither plasma T4 nor plasma T3 levels
alone permit prediction of the degree of change in T4 and T3
concentrations in tissues: not only are the tissue to plasma T4
and T3 ratios different for different tissues, but they may also
change for a single tissue as a function of the plasma iodothyro-
nine level.
Using the information summarized in Tables AI-AIII, we
have calculated the T4 and T3 levels which would be expected
in different tissues when circulating T4 and T3 are comparable
to those of intact controls. These are shown in Fig. 5, A-i-A-
3, superimposed on the normal range of T4 and T3 concentra-
tions for the corresponding tissue.
Fig. 5 A-2 illustrates the finding that a normal plasma T4
level concentration does not ensure that T3 is normal in tissues,
with the notable exception of Cx and Cb, and possibly K, Mu,
and S. Fig. 5 A-3 summarizes the finding that the concentration
of T3 may still be low in some tissues, such as Lu and BAT,
even when infusion of the thyroidectomized rats with T4 has
resulted in normal plasma T3. It would appear that a normal
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Figure 5. (A-i to A-3) The calcu-
lated values of T4 or T3 concen-
trations (horizontal bars) which
would be expected in different tis-
sues of thyroidectomized, T4-in-
fused rats when their circulating
T4 or T3 levels are the same as
those measured in the plasma of
intact control rats. The values
shown in the different panels are
those interpolated from the corre-
sponding equation, as given in Ta-
bles Al-AIII of the Appendix. The
tissue T4 or T3 concentration
which corresponds to the mean
control plasma value is shown as
a vertical line inside the bar,
which extends laterally to the in-
terpolated values corresponding to
the lower and upper 95% confi-
dence intervals (mean±t * SEM)
of the control plasma values. The
shaded area behind the bars corre-
sponds to the mean and 95% con-
fidence intervals of the tissue T4
or T3 concentrations, as measured
in intact control rats. (B-i to B-3)
The calculated values of the circu-
lating T4 or T3 concentrations
(horizontal bars) which would be
needed for the T4 or T3 levels of
thyroidectomized, T4-infused rats
to reach normal control values in
different tissues. The values
shown are those interpolated from
the corresponding equation, as
given in Tables Al-AIR. The
plasma T4 or T3 concentration
which corresponds to the mean
control tissue value is shown as a vertical line inside the bar, which extends laterally to the interpolated values corresponding to the lower and
upper 95% confidence intervals (mean±t SEM) of the tissue levels found in the normal controls. The shaded area behind the bars corresponds to
the mean and 95% confidence intervals of the plasma T4 or T3 concentrations, as measured in intact control rats. All concentrations are expressed
as percentages of the mean control value.
circulating T4 level (Fig. 5 A-i) does not necessarily ensure
that T4 is normal in all tissues: T4 in Mu and Cb are higher
than expected from plasma T4, whereas T4 tends to be low in
H, and possibly K and L.
Using the same information summarized in Tables AI-AIIl
we also calculated the inverse, namely, which circulating T4
and T3 levels would have to be reached to ensure that the T4
and T3 values in each tissue are comparable to those of normal
control rats. The results are shown in the three panels of Fig.
5 B, superimposed on the range of normal plasma T4 or T3
concentrations. Fig. 5, B-J-B-3 stress the unique homeostasis
of cerebral T3, which is normal even with plasma T4 and T3
levels which are clearly in a hypothyroid range. On the contrary,
normalization of lung T3 in the thyroidectomized, T4-infused
rats requires supraphysiological circulating T3. For BAT, the
degree of fit of the data by the equations shown in Tables AI
and All of the Appendix was poorer than for other tissues
studied here. Despite this, the interpolated values shown in the
lower panels of Fig. 5 indicate that T3 did not increase in BAT
above the normal range even at the highest plasma T4 and T3
levels attained in the present study, namely 3.5 and 2.5 times
the mean control values, respectively.
Iodothyronine deiodinase activities
Liver 5'D-I activity decreased from controls values of 52±4
to 16±12 pmol I-/min per mg protein in the placebo-infused
thyroidectomized rats, and increased towards normal activities
in the thyroidectomized rats on 1.0 or 1.6 jtg T4/ 100 gram BW
per day. Liver 5 'D-I activity further increased with the higher
T4 doses, up to 3.5-fold normal values with the dose of 8.0 tg
T4/ 100 gram BW per day.
Lung 5 'D-I activity also decreased from controls values of
557+17 to 144±9 fmol I-/h per mg protein in the placebo-
infused thyroidectomized rats. Activities increased in T4-in-
fused thyroidectomized rats and were within the normal range
in those infused with 1.0 to 4.0 ,4g T4/100 gram BW per day.
Activities increased twofold in the rats receiving 8.0 HIg T4/
100 gram BW per day.
Cerebral cortex 5 'D-II markedly increased in the thyroidec-
tomized rats to 209±14 fmol I-/h per mg protein, as compared
to 33±2 fmol I-/h per mg protein in controls animals. The
activity of this enzyme decreased when T4 was infused, normal
values being found in the thyroidectomized rats infused with
0.6 to 3.0 4g T4/100 gram BW per day, and decreased to
6.3±0.3 fmol I-/h per mg protein in the thyroidectomized rats
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on 4.0 and 8.0 Mg T4/100 gram BW per day. The activity of
the inner-ring 5D-I1 was 2,022±473 fmol I-/h per mg protein
in Cx of the control rats. No statistically significant changes
which were reproducible in both experiments were observed in
the thyroidectomized rats on placebo or T4 infusion.
Discussion
The experimental design. The aim of a hormonal replacement
therapy is to ensure an adequate supply of the missing hormone
in a manner which mimics the normal supply as closely as
possible, and results in normal biological effects, both qualita-
tively and quantitatively. When the thyroid gland is absent or
not capable of synthesizing or secreting T4 and T3, treatment
with T4 is preferred over T3 because it is the main secretory
product of the gland and generates T3 in many tissues, some
of which are a source of systemic T3 distributed throughout the
body by the bloodstream. The mean residence time of T4 in
the rat is 17.4 h (38), and the daily intraperitoneal injection of
the replacement dose in thyroidectomized animals is accompa-
nied by wide daily fluctuations of the plasma and tissue concen-
trations of both T4 and T3 (39), as well as fluctuations of a
biological end-point of action, such as circulating TSH (40).
To avoid this the thyroidectomized rats of the present study
have received a constant subcutaneous infusion of T4, adminis-
tered using osmotic minipumps, which do not require restraint
of the animals, thus allowing free access to food and water.
The period of infusion was 12 or 13 d, which is 17 to 22 times
the mean residence time of T4 in adult rats. Previous studies
by others (16, 17) have shown that adult rats on a constant
infusion of radiolabeled T4 are in equilibrium by 6 (euthyroid
rats) or 8 (hypothyroid rats) d of infusion, when the amounts
of labeled metabolites excreted daily into the feces and urine
become constant and their sum is equivalent to the amount of
radioactivity infused daily. In the present study infusion of T4
was extended well beyond this minimum period. Obviously,
with this mode of administration diurnal rhythms of circulating
T4 and T3, which might be dependent on the circadian varia-
tions in TSH (41), would be abolished. Those rhythms which
are caused by intracellular events, such as those described for
deiodinase activities in several areas of the rat brain (42) or
the pineal gland (43) might, however, still be operative.
Maintenance of euthyroidism in tissues. The aim of the
present study was to test directly whether, or not, a hypothyroid
rat receiving T4 alone is provided with the necessary regulatory
mechanisms to compensate for the lack of thyroidal secretion
of T3, a minor source of T3 available to tissues, and thus ensure
euthyroidism of all tissues simultaneously. There might be sev-
eral criteria for defining euthyroidism, or normal thyroid status,
of a tissue. One criterion might be that the biological effects of
thyroid hormones are the same as in tissues from normal ani-
mals, both qualitatively and quantitatively, another that normal
concentrations of thyroid hormone are provided to the tissue.
The latter criterion assumes that normalization of the iodothyro-
nine content of the tissue would be followed by normalization
of the biological effects. It is at present very difficult to apply
the first of these two criteria, because of the paucity of biological
end-points which we can attribute to direct local effects of the
thyroid hormones in different tissues.
It is therefore necessary to rely on the second criterion for
euthyroidism, which encloses two possibilities, namely, (a) that
both T4 and T3 have to be normal, or (b) that it is enough to
ensure normal T3 concentrations to elicit quantitatively and
qualitatively normal biological end-points.
It is evident from the present results that possibility (a) is
not met, as the administration of T4 alone to thyroidectomized
rats does not result in both normal T4 and T3 simultaneously
in all tissues at any of the 10 doses tested. It is also highly
unlikely that this would have been achieved with an intermedi-
ate dose, possibly between 1.0 and 1.6 Ag T4/100 gram BW
per day. The first of these two doses results in normal circulating
T4 and T3, but plasma TSH is still elevated, and T3 low in
most tissues. The second of these doses results in high plasma
T4, and normal plasma T3 and TSH, but at the expense of
excessive concentrations of T4 in practically all tissues studied.
Even so, T3 may still be low in some tissues. The interpolated
values calculated from the curves best fitting the individual data
also support the conclusion that infusion of T4 alone, even at
doses which were not tested in the present study, is inadequate
to normalize tissue T4 and T3.
The second possibility, namely that it ought to be sufficient
to maintain euthyroidism by normalizing tissue T3 levels re-
flects the prevailing consensus that this ought to ensure normal
T3 receptor occupancy and, as a consequence, normal biological
effects. This concept includes several assumptions, namely, that
T4 per se does not exert any biological effect, that all thyroid
hormone action is exerted through nuclear thyroid hormone
receptors, and that the T3 bound to the receptor is derived from
a single compartment, which does not differentiate between T3
derived from plasma or generated locally in the tissue from T4.
Extranuclear effects of T4 have, however, been described (44).
Moreover, T4 might contribute to nuclear thyroid hormone re-
ceptor occupancy, although to a much lesser degree than T3
(45). If the amount of available T3 is insufficient, T4 occupies
the receptor, and exerts a biological effect (46). It has also
been reported for the rat liver that plasma-derived T3 and T3
generated locally from T4 are in different compartments with
respect to nuclear receptor binding: practically all of the nuclear
T3 appears to be plasma derived (18).
Even if these possibilities are disregarded and normalization
of tissue T3 is considered as an adequate criterion to assess
tissue euthyroidism, it is clear from the present results that a
normal thyroid status is not achieved simultaneously for all
tissues when T4 alone is infused. Lung and BAT T3 were still
low when plasma T3 was normal. Normal T3 concentrations in
many tissues required either supraphysiological concentrations
of T4 in the tissue, elevated activities of iodothyronine deiodi-
nases, or both. We do not know if a long-term adverse effect
might result from high intracellular T4 concentrations, or from
the permanent stimulation of the compensatory mechanisms,
which would increase extracellular formation of T3 from T4.
The continuous increase in TSH secretion needed to ensure
normal plasma T4 in subclinical hypothyroidism is considered
undesirable, and substitution therapy to avoid chronic pituitary
overstimulation is often recommended (47).
Compensatory mechanisms. Present results confirm for nor-
mal adult female rats the tight homeostasis of T3 concentrations
in the Cx when T4 is provided to the hypothyroid animal, al-
ready described for the rat fetus (22) and adult pregnant rat
(48). Cerebral cortex T3 remained within normal limits over a
20-fold increase in the T4 infusion doses, namely from 0.4 to
8.0 tg T4/ 100 gram BW per day. Normalization of T3 is
achieved in the Cx when circulating T4 is half that of normal
control animals, and T4 in the Cx is one-third. This finding is
in conceptual agreement with the marked increase in cerebral
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cortex 5 'D-II activity of hypothyroid rats (49), as measured in
vitro, and confirmed in the present study. The changes of cere-
bral cortex 5 'D-II activity do not, however, appear to offer an
adequate explanation for the maintenance of cerebral cortex T3
homeostasis in rats infused with very high doses of T4, which
resulted in supraphysiological cerebral cortex T4, plasma T4,
and plasma T3 levels. It seems unlikely that the slight inhibition
of 5 'D-II, which was only observed for the animals on the two
highest doses of T4, would be enough to counteract the very
marked increase in the concentration of T4 in the Cx. We also
did not find a systematic increase in SD-Ill activity, which
would contribute to cerebral cortex T3 homeostasis by enhanc-
ing both the degradation of T4 to rT3 and the deiodination of
T3. Obviously, conditions prevailing in vivo might have been
superseded by those used for the enzyme assay in vitro. Even
if SD-Ill activity remained unchanged, the amount of rT3 gener-
ated by inner-ring deiodination of T4 would increase with in-
creasing amounts of available substrate. Reverse T3 is a potent
reversible inhibitor of 5 'D-II (50) and might locally reach in-
hibitory concentrations in vivo. Other possible mechanisms con-
tributing to maintenance of cerebral cortex T3 homeostasis
might involve changes in the availability of endogenous enzyme
cofactors, as described for the liver of fasting rats (51), in the
rates of uptake and/or exit of the iodothyronines (26), or in
nondeiodinative pathways of iodothyronine metabolism (25).
Regarding the latter, sulfation of T4 and T3 leads to the forma-
tion of the sulfo-conjugates, which greatly enhances their inner-
ring and outer-ring deiodination, both sulfo-conjugates being
much better substrates for the selenocisteine-containing 5 'D-I
than the parent iodothyronine (52, 53). Sulfation may thus be
an important metabolic pathway for the deiodinative clearance
of T4 and T3. Sulfotransferase activity is not only high in liver
and kidney, but also in the brain (54, 55). The importance of
this pathway for the maintenance of T3 homeostasis in the Cx
is, however, uncertain, as T3S is not a good substrate for SD-
III (52, 53), and we did not detect appreciable 5'D-I activity
in Cx, Cb, and BAT. This is in conceptual agreement with the
finding that brain microsomes appear to metabolize T3S poorly,
and less rapidly than T3 (55), contrary to findings in the liver.
Moreover, rat-cultured astrocytes do not sulfate T3, but only
the deiodination products of T3 (56). This metabolic pathway
might favor the release of iodothyronine metabolites into the
circulation. To our knowledge, there is no information regarding
formation of T3S by other cells originating from the brain.
Another possibility is that the sigmoidal curve for T3 in the
cortex and cerebellum is mainly determined by the blood-brain
barrier.
Liver 5 'D-I plays an important role in the generation of T3
and T4, and the L is an important source of systemic T3. The
changes in the activity of liver 5'D-I measured in the present
study agree with those expected from previous investigations:
activity decreases in the thyroidectomized rat and then increases
towards normal values, that are not reached until liver and plasma
T3 are normal and plasma and liver T4 are increased approxi-
mately twofold. In animals with normal circulating T4 and T3
the concentrations of the latter iodothyronine are lower than nor-
mal in both P1 and L. Thus, in hypothyroid conditions, the activ-
ity of liver 5 'D-I does not appear to contribute to the normaliza-
tion of plasma-derived T3 in other tissues. This decreased activity
of liver 5 'D-I would have a T4-sparing effect and might contrib-
ute to the normalization of locally generated T3 in tissues with
important local production of T3 from T4, such as Cx.
Normalization of T3 concentrations in Lu required even
higher infusion doses of T4 than normalization of T3 in L. Triio-
dothyronine in Lu was lower than normal even when normal
plasma T3 levels were reached. The measured changes in lung
5 'D-I activity do not afford an explanation for this finding, unless
locally generated T3 is rapidly exported into the circulation. The
findings for BAT T3 were similar to those for lung T3, inasmuch
as BAT T3 reached normal values when plasma T3 was higher
than normal. This could be in agreement with the reported finding
that BAT represents and important source of systemic T3
(23, 24).
An unexpected finding was that skeletal muscle T4 became
normal in rats on a T4 dose which was insufficient to ensure
normal plasma T4, and became higher than normal in animals
with normal circulating T4. Skeletal muscle T3 was also normal
in animals with low circulating T3 levels, but with higher than
normal concentrations of T4 in the tissue. Local conversion of
T4 to T3 generates a very minor proportion of T3 in thigh muscle
of hypothyroid rats (1.5-3.7%) and none in euthyroid animals
(16), and does not afford an explanation for the latter finding.
In summary, when T4 alone is administered as replacement
therapy to thyroidectomized rats, compensatory regulatory
mechanisms are unable to provide both normal T4 and T3 con-
centrations simultaneously in plasma and all tissues. They are
also inadequate to at least ensure normal concentrations of T3
in all tissues, even at the expense of excessive T4 concentra-
tions. The dose of T4 needed to normalize thyroid hormone
concentrations is different for each tissue, thus pointing to the
existence of tissue-specific regulatory mechanisms. Of the tis-
sues studied, Cx showed a very efficient homeostasis of its
T3 concentrations, providing metabolic protection of this organ
against wide changes in thyroid hormone availability.
The infusion of T3 to thyroidectomized rats is also inade-
quate to ensure normal T3 levels simultaneously in plasma and
all tissues (57), whereas preliminary data show that the com-
bined infusion of T4 and T3, in a molar ratio similar to that of
the thyroidal production, does ensure both normal T4 and T3
in all tissues (58).
Possible clinical implications. The possibility that the pres-
ent findings in the rat might also be relevant for humans raises
questions regarding the current treatment of hypothyroidism
with T4 alone as replacement therapy. There are differences
between our experimental model and thyroid replacement ther-
apy in humans. The usual clinical practice entails the oral ad-
ministration of a single daily dose of T4. We have preferred
delivery of T4 by a continuous subcutaneous infusion of T4, to
avoid marked daily fluctuations in circulating thyroid hormone
levels. The differences between these two types of delivery,
however, might not be very great if we consider the mean
residence time for T4 in both species, namely 310 and 17.4 h
in humans and rats, respectively (40). When T4 is given daily,
the patient receives 13 doses within the period of mean T4
residence time; fluctuations of serum T4 are likely to be buf-
fered. This might be roughly equivalent in the rat to 13 doses
during a 17.4-h period, which may be considered almost equiva-
lent to constant infusion. The 12-13-d infusion period is several
days longer than the minimum time needed to achieve a steady
state situation in hypothyroid rats (16, 17). If we again take
the mean residence time in both species as a plausible basis for
comparisons, a 12-d infusion period in the rat would be equiva-
lent to 16.6 times the mean T4 residence time; this would be
roughly equivalent to 5,146 h in man (16.6-310 h), or 7 mo
of treatment. This is usually considered adequate to achieve
stable thyroid hormone concentrations (27).
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The relative importance of thyroidal T3 secretion versus T3
generation from T4 is likely to be greater in rats than humans,
as the molar ratio of T4 to T3 in the respective thyroidal secre-
tion is - 6:1 (2-5), and 14:1 (1). This might represent an
important difference between the present experimental model
and the situation in patients, as in humans the thyroidal secretion
of T3 might be more easily replaced by T3 generated from T4.
On the other hand, we have practically no information regarding
the compensatory mechanisms responding to hypo- and hyper-
thyroidism in humans, or the concentrations of T4 and T3 in
tissues of normal people or T4-treated patients. There are data,
however, which strongly suggest that present main conclusions
are relevant for patients, inasmuch as peripheral compensatory
mechanisms do not provide adequate circulating levels of both
T4 and T3 in hypothyroid patients on T4: for similar plasma
levels of T3 and TSH (59) patients on T4 replacement therapy
present higher circulating T4 than normal controls. This situa-
tion is the same we have found in the present experimental
study, and suggests that similarities may well exist as regards
tissue concentrations of T3 and T4. If our results are shown
to be pertinent in humans, the current replacement therapy of
hypothyroidism should no longer be considered adequate, and
might possibly lead to the development of new strategies of
therapy combining administration of both T4 and T3, albeit at
a much higher T4 to T3 molar ratio (possibly 14:1 ) than pre-
viously used clinically (4:1) (60).
Appendix
Table AL Results of the Curve Fitting between Tissue T4 and
Plasma T4 of Thyroidectomized Rats Infused with T4 Alone*
Tissue Fit' Formula R2 d.f. F
Cortex Power [Cx-T4] = 0.59 [PI-T4](t 12) 0.82 50 224
Cerebellum Sigmoidal [Cb-T4] = e(538-5l.l2/[PI-T4]) 0.88 50 354
BAT Sigmoidal [BAT-T4] = e(513-2709/[PI-T4]) 0.59 50 71
Liver Power [L-T4] = 0.038- [PI-T4]166) 0.79 49 181
Kidney Linear [K-T4] = -6.62 + 0.86- [P1-T4] 0.84 51 268
Lung Sigmoidal [Lu-T4] = e(5.26-50.9/1P1-T41) 0.86 48 302
Heart Power [H-T4] = 0.58 [PI-T4](1 06) 0.91 49 472
Muscle Power [Mu-T4] = 1.61 [P1-T4](097) 0.87 51 346
Spleen Power [S-T4] = 1.02 [PI-T4](103) 0.90 50 426
* Before curve fitting, and to combine the results of experiments A and B, raw
data were transformed in percent of the mean value of the control group. The
95% confidence interval for the normal plasma T3 and T4 concentrations was
87-113% of mean control values (T4: 36 ng/ml, T3: 0.84 ng/ml). I The curve
with the best fitting (defined by the highest R2 and F values) was selected. All
fittings were significant with P < 0.001.
Table All. Results of the Curve Fitting between Tissue T3 and
Plasma T4 of Thyroidectomized Rats Infused with T4 Alone*
Tissue Fit Formula R2 d.f. F
Cortex Inverse [Cx-T3] = 117 - (1300/[P1-T4]) 0.79 47 173
Cerebellum Sigmoidal [Cb-T3] = e(493-3469/IPI-T4]) 0.84 47 251
BAT Sigmoidal [BAT-T3] = e(456-2754/[PI-T4]) 0.60 47 69
Liver Linear [L-T3] = -8.22 + 0.77 [Pl-T4] 0.74 47 132
Kidney Linear [K-T3] = 1.05 + 0.80- [Pl-T4] 0.73 47 125
Lung Power [Lu-T3] = 0.47- [Pl-T4](1.03) 0.83 45 221
Heart Power [H-T3] = 0.53 [Pl-T4](l 02) 0.82 48 224
Muscle Power [Mu-T3] = 1.39*[PI-T4](089) 0.85 48 275
Spleen Power [S-T3] = 3.82- [PI-T4](068) 0.89 49 385
* See legend to Table Al.
Table AIJI. Results of the Curve Fitting between Tissue T3 and
Plasma T3 of Thyroidectomized Rats Infused with T4 Alone*
Tissue Fit Formula R2 d.f. F
Cortex Inverse [Cx-T3] = 128 - (1923/[PI-T3]) 0.88 45 334
Cerebellum Sigmoidal [Cb-T3] = e(5.l8-4972/[PIIT3]) 0.86 43 265
BAT Sigmoidal [BAT-T3] = e(475-39.9/[PI-T3]) 0.53 47 53
Liver Linear [L-T3] = -19.94 + 1.18- [Pl-T3] 0.91 50 521
Kidney Linear [K-T3] = -11.60 + 1.22- [Pl-T3] 0.88 49 361
Lung Power [Lu-T3] = 0.15- [P1-T3]j('14) 0.91 47 469
Heart Sigmoidal [H-T3] = e(5.15-60.5/lPI-T3l) 0.88 45 337
Muscle Power [Mu-T3] = 0.53 [Pl-T3](1.15) 0.87 51 346
Spleen Power [S-T3] = 1.73* [Pl-T31(89) 0.95 48 963
* See legend to Table Al.
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